Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Nursing Ethical Principles II01:27

Nursing Ethical Principles II

Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The CNO-CFO Dyad: A Strategic Driver of Organizational Performance.

The Journal of nursing administration·2026
Same author

What's Old Is New Again, Unfortunately.

Clinical journal of oncology nursing·2026
Same author

A Cancer Disparities Focus Without Acronyms.

Clinical journal of oncology nursing·2026
Same author

The Limits of Staying in Your Lane: Why Nursing Science Needs DNP-PhD Collaboration.

Clinical journal of oncology nursing·2026
Same author

Quantifying acute care nurses' experiences of patient handoffs during shift change: a cross-sectional study.

BMC nursing·2025
Same author

More Than Moderation: A New Era in Oncology Health Promotion.

Clinical journal of oncology nursing·2025

Related Experiment Video

Updated: Jun 3, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

GLP-1 Medications in Oncology Nursing Practice.

Joni L Watson1

  • 1Joni L. Watson.

Clinical Journal of Oncology Nursing
|June 2, 2026
PubMed
Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are being investigated for potential cancer links. Current evidence is evolving and conflicting, prompting further clinical inquiry into these widely used medications.

Area of Science:

  • Endocrinology and Metabolism
  • Oncology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes and obesity.
  • The physiological effects and long-term outcomes of GLP-1 RAs have raised questions regarding their potential association with cancer development.
  • Existing scientific literature presents conflicting evidence on the relationship between GLP-1 RA use and cancer risk.

Purpose of the Study:

  • To critically evaluate the current body of evidence regarding the association between GLP-1 receptor agonists and cancer.
  • To synthesize conflicting findings and identify areas requiring further investigation in the context of clinical practice.

Main Methods:

  • Systematic review of preclinical studies and clinical trials investigating GLP-1 RAs and cancer.
Keywords:
GIPGLP-1evidence-based practiceoncology nursingsymptom management

More Related Videos

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

  • Analysis of epidemiological data and meta-analyses examining cancer incidence in patients using GLP-1 RAs.
  • Evaluation of the biological mechanisms proposed to link GLP-1 RAs to tumorigenesis or tumor suppression.

    • Main Results:

    • Preclinical studies suggest potential mitogenic effects of GLP-1 on certain cell types, while others indicate anti-proliferative properties.
    • Clinical data remain inconsistent, with some studies reporting no significant increase in cancer risk and others suggesting potential associations with specific cancer types.
    • The overall evidence does not establish a definitive causal link between GLP-1 RA use and cancer.

    Conclusions:

    • The relationship between GLP-1 RAs and cancer is complex and not yet fully elucidated.
    • Further high-quality, long-term studies are necessary to clarify the potential oncogenic or anti-oncogenic effects of GLP-1 RAs.
    • Clinicians should remain informed about evolving evidence while considering the established benefits of GLP-1 RAs for metabolic diseases.